BridgeBio Pharma (BBIO) CEO’s family trusts sell 80,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. reported that family trusts associated with CEO Neil Kumar sold a total of 80,000 shares of common stock in open‑market transactions. The sales occurred on June 4 and 5, 2026 at prices generally between about $65 and $69 per share.
The transactions were executed under a pre‑arranged Rule 10b5‑1 sales plan adopted on March 31, 2025, and were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where Kumar serves as co‑trustee. He also holds 243,327 shares directly and disclaims beneficial ownership of the trust shares beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
CEO‑related trusts sold 80,000 BridgeBio shares under a pre‑planned Rule 10b5‑1 program, while retaining large ongoing holdings.
Family trusts associated with CEO Neil Kumar completed open‑market sales totaling 80,000 shares of BridgeBio Pharma common stock on June 4–5, 2026. Reported sale prices generally ranged from about $65 to $69.51 per share, based on weighted‑average price ranges in the footnotes.
The filing shows 100% of reported transactions in this period were sales, with no option exercises or gifts, and a net change of -80,000 shares. The trades were executed under a Rule 10b5‑1 sales plan, indicating they were pre‑scheduled. Kumar continues to hold shares directly and through the trusts, so this appears as a routine, planned reduction rather than a full exit.
Insider Trade Summary 10b5-1
Net Seller: 80,000 shares ($5,413,289)
Net Sell
15 txns
Insider
Kumar Neil
Role
Chief Executive Officer
Sold
80,000 shs ($5.41M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,147 | $67.199 | $480K |
| Sale | Common Stock | 8,437 | $67.8848 | $573K |
| Sale | Common Stock | 4,416 | $68.9593 | $305K |
| Sale | Common Stock | 7,148 | $67.199 | $480K |
| Sale | Common Stock | 8,437 | $67.8848 | $573K |
| Sale | Common Stock | 4,415 | $68.9593 | $304K |
| Sale | Common Stock | 2,200 | $65.7202 | $145K |
| Sale | Common Stock | 1,429 | $66.723 | $95K |
| Sale | Common Stock | 15,921 | $67.7378 | $1.08M |
| Sale | Common Stock | 450 | $68.2697 | $31K |
| Sale | Common Stock | 2,200 | $65.7202 | $145K |
| Sale | Common Stock | 1,429 | $66.723 | $95K |
| Sale | Common Stock | 15,921 | $67.7377 | $1.08M |
| Sale | Common Stock | 450 | $68.2697 | $31K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 528,539 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.);
Common Stock — 243,327 shares (Direct, null)
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Represents the weighted average sale price of the shares sold from $66.15 to $67.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $67.17 to $68.16 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $68.17 to $68.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $66.59 to $67.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $67.61 to $68.605 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $68.61 to $69.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Key Figures
Shares sold: 80,000 shares
Sale price range: $65.145–$69.51 per share
Direct holding: 243,327 shares
+4 more
7 metrics
Shares sold
80,000 shares
Open-market sales on June 4–5, 2026 by family trusts
Sale price range
$65.145–$69.51 per share
Weighted-average price ranges disclosed in footnotes
Direct holding
243,327 shares
Common stock held directly as of June 4, 2026
Revocable trust holding
4,318,447 shares
Total shares reported after a June 5, 2026 sale
Family irrevocable trust holding
515,686 shares
Total shares reported after a June 5, 2026 sale
Sell transactions count
14 transactions
Open-market sale entries in this Form 4
Net insider share change
-80,000 shares
Net buy/sell shares in the reporting period
Key Terms
Rule 10b5-1 sales plan, weighted average sale price, beneficial ownership, pecuniary interest, +1 more
5 terms
Rule 10b5-1 sales plan financial
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025."
weighted average sale price financial
"Represents the weighted average sale price of the shares sold from $65.145 to $66.12 per share."
beneficial ownership financial
"this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any."
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
At what prices did the BridgeBio Pharma (BBIO) insider sales occur?
The reported sales occurred at weighted‑average prices generally between about $65.145 and $69.51 per share. Footnotes specify narrower ranges for trade groups, and the reporting person offers to provide exact breakdowns of shares sold at each individual price upon request.
Did the BridgeBio (BBIO) Form 4 include any option exercises or only stock sales?
The Form 4 reflects only open‑market sales of common stock, with no reported option exercises or derivative transactions. The transaction summary lists 14 sale transactions totaling 80,000 shares and indicates zero exercise, gift, or tax‑withholding entries in this reporting period.